Literature DB >> 28693173

Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy.

Khalid Al-Saleh1, Nashwa Abd El-Aziz1,2, Arwa Ali1,2, Waleed Abozeed1,3, Ahmed Abd El-Warith1,4, Ahmed Ibraheem1, Jawaher Ansari1, Ammar Al-Rikabi5, Sufia Husain5, Jean-Marc Nabholtz1.   

Abstract

The immunobiology of breast cancer (BC) subtypes, including luminal cancer, remains unclear. Cluster of differentiation (CD)8+ tumor-infiltrating lymphocytes (TIL) are essential components of tumor-specific cellular adaptive immunity. However, only few studies have addressed the significance of cluster of differentiation 8+(CD8+) TIL in patients with luminal BC. The present study aimed to evaluate the predictive and prognostic significance of CD8+ TIL in patients with luminal B/human epidermal growth factor receptor 2 (HER 2)-negative BC treated with anthracycline-based neoadjuvant chemotherapy (NC). A total of 31 patients who underwent breast-conserving surgery or mastectomy post-NC were enrolled. Immunostaining for CD8+ TIL was performed using rabbit monoclonal antibodies against human CD8+. Intra- and peritumoral CD8+ TIL expression levels were classified into high and low, based on the median value of each. CD8+ TIL expression data were demonstrated to be correlated with disease-free survival (DFS) and overall survival (OS), using Kaplan-Meier and Cox's proportional hazards regression tests. The results revealed that, among all clinicopathological characteristics, only pathological complete response (pCR) was significantly correlated with intratumoral CD8+ TIL expression (P=0.016). A total of 9/16 patients (56%) with high intratumoral CD8+ TIL expression achieved pCR, in contrast with 2 out of 15 patients (13.3%) with low expression (P=0.016). High expression of intratumoral CD8+ TIL was significantly associated with OS (log-rank test, P=0.023). Multivariate Cox regression analysis revealed that intratumoral expression of CD8+ TIL was an independent prognostic factor for OS [hazard ratio (HR)=2.82; 95% confidence interval (CI)=0.911-4.833, P=0.007], but not for DFS (HR=1.11; 95% CI=0.282-2.078; P=0.508). In conclusion, the results of the present study suggested that high intratumoral CD8+ TIL expression was significantly predictive of pCR post-NC, and represented an independent prognostic factor for improved OS. In contrast, low intratumoral CD8+ TIL expression was a strong predictor of lack of pCR to NC, as well as an independent prognostic factor for poor OS. Assessment of the immune response in conjunction with the usual parameters may aid in the further stratification of patients with luminal B/HER 2-negative BC regarding the prediction of pCR post-NC and overall prognosis.

Entities:  

Keywords:  breast cancer; cluster of differentiation 8+; human epidermal growth factor receptor 2-negative; luminal B; lymphocytes; neoadjuvant chemotherapy; prediction; prognosis

Year:  2017        PMID: 28693173      PMCID: PMC5494820          DOI: 10.3892/ol.2017.6144

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  47 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.

Authors:  Stuart J Schnitt
Journal:  Mod Pathol       Date:  2010-05       Impact factor: 7.842

4.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

5.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Authors:  Aleix Prat; Maggie Chon U Cheang; Miguel Martín; Joel S Parker; Eva Carrasco; Rosalía Caballero; Scott Tyldesley; Karen Gelmon; Philip S Bernard; Torsten O Nielsen; Charles M Perou
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

6.  The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer.

Authors:  Rafal Matkowski; Iwona Gisterek; Agnieszka Halon; Aleksandra Lacko; Krzysztof Szewczyk; Urszula Staszek; Marek Pudelko; Bartlomiej Szynglarewicz; Jolanta Szelachowska; Andrzej Zolnierek; Jan Kornafel
Journal:  Anticancer Res       Date:  2009-07       Impact factor: 2.480

7.  Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Authors:  Osamu Kawai; Genichiro Ishii; Kaoru Kubota; Yukinori Murata; Yoichi Naito; Tetsuya Mizuno; Keiju Aokage; Nagahiro Saijo; Yutaka Nishiwaki; Akihiko Gemma; Syoji Kudoh; Atsushi Ochiai
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

Review 8.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

9.  Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Hee Jin Lee; Jin-Young Seo; Jin-Hee Ahn; Sei-Hyun Ahn; Gyungyub Gong
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

10.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Authors:  H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas
Journal:  Ann Oncol       Date:  2014-06-09       Impact factor: 32.976

View more
  14 in total

1.  Protein-based immune profiles of basal-like vs. luminal breast cancers.

Authors:  Andrea Walens; Linnea T Olsson; Xiaohua Gao; Alina M Hamilton; Erin L Kirk; Stephanie M Cohen; Bentley R Midkiff; Yongjuan Xia; Mark E Sherman; Nana Nikolaishvili-Feinberg; Jonathan S Serody; Katherine A Hoadley; Melissa A Troester; Benjamin C Calhoun
Journal:  Lab Invest       Date:  2021-02-23       Impact factor: 5.662

2.  The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.

Authors:  Hanjiao Qin; Linlin Liu; Shu Sun; Dan Zhang; Jiyao Sheng; Bingjin Li; Wei Yang
Journal:  PeerJ       Date:  2018-06-19       Impact factor: 2.984

3.  Role of regulatory T cells and CD8+ T lymphocytes in the dissemination of circulating tumor cells in primary invasive breast cancer.

Authors:  Dandan Xue; Tiansong Xia; Jue Wang; Meihong Chong; Shui Wang; Chunhui Zhang
Journal:  Oncol Lett       Date:  2018-06-19       Impact factor: 2.967

4.  Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy.

Authors:  Wataru Goto; Shinichiro Kashiwagi; Yuka Asano; Koji Takada; Katsuyuki Takahashi; Takaharu Hatano; Tsutomu Takashima; Shuhei Tomita; Hisashi Motomura; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira
Journal:  ESMO Open       Date:  2018-08-30

5.  Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma.

Authors:  Jingjing Chen; Ping Gu; Haibo Wu
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

Review 6.  Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.

Authors:  Maria Vittoria Dieci; Federica Miglietta; Valentina Guarneri
Journal:  Cells       Date:  2021-01-23       Impact factor: 6.600

7.  Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer.

Authors:  Yunxuan Wang; Tieying Dong; Qijia Xuan; Hong Zhao; Ling Qin; Qingyuan Zhang
Journal:  J Breast Cancer       Date:  2018-06-20       Impact factor: 3.588

8.  CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments.

Authors:  Gage Brummer; Wei Fang; Curtis Smart; Brandon Zinda; Nadia Alissa; Cory Berkland; David Miller; Nikki Cheng
Journal:  Oncogene       Date:  2019-12-11       Impact factor: 9.867

9.  Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study.

Authors:  Carlos López; Ramón Bosch-Príncep; Guifré Orero; Laia Fontoura Balagueró; Anna Korzynska; Marcial García-Rojo; Gloria Bueno; Maria Del Milagro Fernández-Carrobles; Lukasz Roszkowiak; Cristina Callau Casanova; M Teresa Salvadó-Usach; Joaquín Jaén Martínez; Albert Gibert-Ramos; Albert Roso-Llorach; Andrea Gras Navarro; Marta Berenguer-Poblet; Montse Llobera; Júlia Gil Garcia; Bárbara Tomás; Vanessa Gestí; Eeva Laine; Benoít Plancoulaine; Jordi Baucells; Maryléne Lejeune
Journal:  PeerJ       Date:  2020-09-02       Impact factor: 2.984

10.  Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler.

Authors:  Helga Bergholtz; Jodi M Carter; Alessandra Cesano; Maggie Chon U Cheang; Sarah E Church; Prajan Divakar; Christopher A Fuhrman; Shom Goel; Jingjing Gong; Jennifer L Guerriero; Margaret L Hoang; E Shelley Hwang; Hellen Kuasne; Jinho Lee; Yan Liang; Elizabeth A Mittendorf; Jessica Perez; Aleix Prat; Lajos Pusztai; Jason W Reeves; Yasser Riazalhosseini; Jennifer K Richer; Özgür Sahin; Hiromi Sato; Ilana Schlam; Therese Sørlie; Daniel G Stover; Sandra M Swain; Alexander Swarbrick; E Aubrey Thompson; Sara M Tolaney; Sarah E Warren
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.